期刊文献+

重组人血管内皮抑素联合顺铂治疗鼠B16恶性黑色素瘤移植模型的实验研究 被引量:12

Effects of recombinant human endostatin combined of cisplatin on the growth of xenografled malignant melanoma in nude mouse
下载PDF
导出
摘要 目的探讨重组人内皮抑素(恩度)联合顺铂化疗对恶性黑色素瘤的作用。方法建立B16恶性黑色素瘤的裸鼠移植模型20只,随机分为恩度组、顺铂组、恩度联合顺铂组(联合组)和对照组。治疗后处死裸鼠,计算肿瘤体积抑瘤率,用免疫组化法测微血管密度(MVD)及瘤体血管内皮生长因子(VEGF)的表达。结果恩度组、顺铂组和恩度联合顺铂组(联合组)的肿瘤抑制率分别为17.52%、45.72%和59.40%,联合组的肿瘤生长明显受到抑制(P<0.05)。免疫组化结果显示,联合组MVD低于其他组(P<0.05);恩度组、顺铂组和联合组的VEGF表达均明显低于对照组(P<0.05)。结论恩度联合顺铂有协同抗肿瘤作用,能有效抑制恶性黑色素瘤的生长。 Objective To study the effect of recombinant human endostatin(YH-16,endostar)combined with cisplatin(DDP)on the growth of xenografted malignant melanoma in nude mouse.Methods After the establishment of the model,mice were divided into 4 groups with five mice each.The drug was given intraperitoneally for consecutive 10 or 14 days:PBS (0.2ml/d for 1 to 14 days d1-14),DDP (2mg·kg^-1·d^-1,for 1 to 10 days),YH-16 (1.5mg·kg^-1·d^-1,for 1 to 14 days),and DDP + YH-16. Tumor volume was measured on the 21st day.The expression of vascular endothelial growth factor(VEGF) was examined.The tumor inhibition rate (TIR) was calculated.Results TIR of YH-16 group,DDP group and YH-16 +DDP group was 17.52%,45.72% and 59.40%,respectively.Tumor growing of YH-16 +DDP group was inhibited significantly (P〈0.05).Microvascular dentity(MVD) of YH-16 +DDP group was also less than that of the other groups(P〈0.05).The expression of VEGF in YH-16 group,DDP group and YH-16+DDP group was remarkably degressed(P〈0.05).Conclusion YH-16 in combination with DDP has synergistic effect on inhibitory activity against the growing of malignant melanoma.
出处 《江苏医药》 CAS CSCD 北大核心 2008年第5期506-508,共3页 Jiangsu Medical Journal
关键词 重组人内皮抑素 顺铂 恶性黑色素瘤 Recombinant human endostatin Cisplatin Malignant melanoma
  • 相关文献

参考文献13

  • 1Toi M, Hoshina S, Takayanagi T, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early replase in primary breast cancer[J]. Jpn J Cancer Res, 1994,85 (10) : 1045-1049.
  • 2Weidner N. Intratumor microvessel density as a prognostic factor in cancer[J]. Am J Pathol, 1995,147(1) :9-15.
  • 3O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997,88(2) :277-285.
  • 4Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J]. Exp Cell Res, 2006,312(5):594- 607.
  • 5Cho H, Kim WJ, Lee YM, et al. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent[J]. Oncol Rep, 2004,11 (1) : 191-195.
  • 6Mendoza L, Valcarcel M, Carrascal T, et al. Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis[J ]. Cancer Res, 2004,64 (1) = 304-310.
  • 7Kirsch M, Weigel P, Pinzer T, et al. Therapy of hematogenous melanoma brain metastases with endostatin[J]. Clin Cancer Res, 2005,11 (3) : 1259-1267.
  • 8Abraham D, Abri S, Hofmann M, et al. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts [J]. J Urol, 2003,170(4) : 1388-1393.
  • 9Subramanian IV, Bui Nguyen TM, Truskinovsky AM, et al.Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival[J]. Cancer Res, 2006,66 (8): 4319-4328.
  • 10吴莹,赵敏,杨莉,刘健,魏于全,赵霞.内皮抑素基因治疗对癌性腹水抑制效应研究[J].四川大学学报(医学版),2004,35(3):316-319. 被引量:46

二级参考文献40

  • 1杨林,王金万,汤仲明,刘秀文,黄镜,李树婷,董英,张和平,薛岚,储大同,孙燕.重组人血管内皮抑制素Ⅰ期临床研究[J].中国新药杂志,2004,13(6):548-553. 被引量:154
  • 2周清华,孙燕.加强我国肺癌分子靶向治疗基础和临床研究[J].中国肺癌杂志,2004,7(4):267-269. 被引量:51
  • 3杨林,王金万,崔成旭,黄镜,张和平,李树亭,孙燕.重组人血管内皮抑制素YH-16联合用药治疗晚期非小细胞肺癌的多中心Ⅱ期临床试验[J].中国新药杂志,2005,14(2):204-207. 被引量:116
  • 4Tamsma JT, Keizer HJ, Meinders AE. Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann Oncol,2001;12(10):1353.
  • 5Frank A. Scappaticci Mechanisms and future directions for angiogenesis-based cancer therapies. Journal of Clinical Oncology,2002;20(18):3906.
  • 6Kruger EA, Duray PH, Tsokos MG, et al. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun,2000;268(1):183.
  • 7Hitoshi Yoshiji, Shigeki Kuriyama, Daniel J.et al. The vascular endothelial growth factor receptor KDR/FIK-1 is a major regulator of malignant ascites for mation in the mouse hapatocellular carcinoma model. Hepatology,2001;33(4):841.
  • 8O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell,1997;88(2):277.
  • 9Noriko Yamaguchi, Bela Anand-Apte, Margaret Lee, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J,1999; 18(16):4414.
  • 10Kyoichi Takahashi, Yoshitsugu Saishin, Yumiko Saishin, et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J,2003;17(8):896.

共引文献660

同被引文献74

引证文献12

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部